Side effects compromise the blinding in clinical studies
Clinical trial evidence confirms that noticeable side effects can compromise study blinding by revealing treatment allocations to participants and personnel.
The retrieved literature contains multiple specific examples demonstrating that adverse events and side effects (such as skin reactions, distinctive psychoactive effects, or lisinopril-induced cough and angioedema) can cause unblinding in clinical studies. No papers contradict this premise.
Giao Do-Pham, Annabel Maruani, Sophie Leducq, Bruno Giraudeau, Olivier Chosidow. Specific-class Skin Side-effects of Drugs Might Compromise Blinding in Randomized Controlled Trials. 2023. https://doi.org/10.2340/actadv.v103.3364
Demonstrates that specific class skin side-effects of drugs can compromise blinding in randomized controlled trials.
See more details
Dankishiya FS, Muhammad H, Wudil UJ, Musa BM, Du L, Adam IA, Ahonkhai AA, Burgner AM, Nalado AM, Sani MU, Abdu A, Shepherd BE, Aliyu MH, Wester CW. Safety and tolerability of the ACE-inhibitor lisinopril among Nigerian adults with HIV: preliminary pilot data from a randomized clinical trial.. 2026. https://doi.org/10.1007/s00210-026-05280-2
Notes that adverse events like persistent cough and angioedema led to unblinding in participants taking lisinopril.
Suresh Muthukumaraswamy. Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis. 2023. https://doi.org/10.31234/osf.io/d52ay
Highlights how distinctive psychoactive side effects cause unblinding and expectancy effects in psychedelic randomized controlled trials.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt